Page 21234..1020..»

Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

By Dr. Matthew Watson

SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update. The Company’s press release concerning its financial results will be available after 1 p.m. Pacific Time on November 22, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021 on that date.

View original post here:
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

To Read More: Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
categoriaGlobal News Feed commentoComments Off on Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update | dataNovember 22nd, 2021
Read All

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

By Dr. Matthew Watson

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.

Read the rest here:
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

To Read More: Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference | dataNovember 22nd, 2021
Read All

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

By Dr. Matthew Watson

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021.

Read more:
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

To Read More: Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference | dataNovember 22nd, 2021
Read All

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee.

Visit link:
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataNovember 22nd, 2021
Read All

Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter

By Dr. Matthew Watson

TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) and disclosing receipt of a Nasdaq Listing delinquency letter.

Read the rest here:
Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter

To Read More: Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter
categoriaGlobal News Feed commentoComments Off on Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter | dataNovember 22nd, 2021
Read All

PacBio Grants Equity Incentive Award to New Employee

By Dr. Matthew Watson

MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on November 15, 2021.

See the rest here:
PacBio Grants Equity Incentive Award to New Employee

To Read More: PacBio Grants Equity Incentive Award to New Employee
categoriaGlobal News Feed commentoComments Off on PacBio Grants Equity Incentive Award to New Employee | dataNovember 22nd, 2021
Read All

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acer’s recent corporate developments.

See the original post:
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

To Read More: Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update | dataNovember 22nd, 2021
Read All

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

By Dr. Matthew Watson

SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovance’s common stock to seven new non-executive employees.

Originally posted here:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

To Read More: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | dataNovember 22nd, 2021
Read All

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

By Dr. Matthew Watson

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Read more:
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

To Read More: Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
categoriaGlobal News Feed commentoComments Off on Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor | dataNovember 22nd, 2021
Read All

Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

By Dr. Matthew Watson

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Read more:
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

To Read More: Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
categoriaGlobal News Feed commentoComments Off on Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility | dataNovember 22nd, 2021
Read All

Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt

By Dr. Matthew Watson

VANCOUVER, British Columbia, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF), a growth-oriented and diversified company focused on the international cannabis industry, announces that its Board of Directors has approved the Company’s issuance of 8,744 common shares (the “Shares”) at a deemed price of $0.84 per Share as payment of the portion of the quarterly amount of interest due in Shares on a loan entered into in December of 2020. All Shares issued will be subject to a minimum hold period of four months and one day from the date of issuance.

Read more:
Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt

To Read More: Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt
categoriaGlobal News Feed commentoComments Off on Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt | dataNovember 22nd, 2021
Read All

OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

By Dr. Matthew Watson

Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149

Read the original:
OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

To Read More: OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures
categoriaGlobal News Feed commentoComments Off on OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures | dataNovember 22nd, 2021
Read All

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Link:
Obseva Announces Appointment of Stephanie Brown to its Board of Directors

To Read More: Obseva Announces Appointment of Stephanie Brown to its Board of Directors
categoriaGlobal News Feed commentoComments Off on Obseva Announces Appointment of Stephanie Brown to its Board of Directors | dataNovember 22nd, 2021
Read All

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

By Dr. Matthew Watson

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Read more here:
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

To Read More: Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
categoriaGlobal News Feed commentoComments Off on Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix | dataNovember 22nd, 2021
Read All

Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen…

By daniellenierenberg

This article was originally published here

Sci Rep. 2021 Nov 5;11(1):21722. doi: 10.1038/s41598-021-01071-2.

ABSTRACT

Spinal cord regeneration is limited due to various obstacles and complex pathophysiological events after injury. Combination therapy is one approach that recently garnered attention for spinal cord injury (SCI) recovery. A composite of three-dimensional (3D) collagen hydrogel containing epothilone B (EpoB)-loaded polycaprolactone (PCL) microspheres (2.5 ng/mg, 10 ng/mg, and 40 ng/mg EpoB/PCL) were fabricated and optimized to improve motor neuron (MN) differentiation efficacy of human endometrial stem cells (hEnSCs). The microspheres were characterized using liquid chromatography-mass/mass spectrometry (LC-mas/mas) to assess the drug release and scanning electron microscope (SEM) for morphological assessment. hEnSCs were isolated, then characterized by flow cytometry, and seeded on the optimized 3D composite. Based on cell morphology and proliferation, cross-linked collagen hydrogels with and without 2.5 ng/mg EpoB loaded PCL microspheres were selected as the optimized formulations to compare the effect of EpoB release on MN differentiation. After differentiation, the expression of MN markers was estimated by real-time PCR and immunofluorescence (IF). The collagen hydrogel containing the EpoB group had the highest HB9 and ISL-1 expression and the longest neurite elongation. Providing a 3D permissive environment with EpoB, significantly improves MN-like cell differentiation and maturation of hEnSCs and is a promising approach to replace lost neurons after SCI.

PMID:34741076 | DOI:10.1038/s41598-021-01071-2

Read this article:
Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen...

To Read More: Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen…
categoriaSpinal Cord Stem Cells commentoComments Off on Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen… | dataNovember 8th, 2021
Read All

Stem Cell & Regenerative Medicine Center University of …

By daniellenierenberg

UW Health treats first patient in U.S. with investigational cell therapy for heart disease

Appleton resident Donald Krause became the first patient in the country last week to undergo an investigational cell therapy for a debilitating heart condition called chronic myocardial ischemia (CMI). Krause was treated by Amish Raval, MD, an interventional cardiologist at UW Health, supported by Peiman Hematti, MD, a bone marrow transplantation hematologist at the UW School of Medicine and Public Health.

October 29, 2021SMPH News

Center members Dr. Anita Bhattacharyy and Dr. Su-Chun Zhang, in collaboration with Waisman and the University of Washington-Seattle and Seattle Childrens Hospital, have been awarded an $11 million Transformative Research grant from the National Institutes of Health to create a new approach using stem cells that may reveal how brain development in individuals with Down syndrome differs from typically developing individuals, identify features that will help understand their intellectual disability, and find potential targets for therapy. They will also address questions that remain unanswered about brain development overall.

October 7th, 2021UW News

The U.S. Food and Drug Administration on Tuesday approved StrataGraft, a topical treatment for severe burns made from skin tissue, providing a boost for Madison-based firm Stratatech. Stratatech was founded in 2000 by SCRMC member Lynn Allen-Hoffman, the first female University of Wisconsin-Madison faculty member to start a biotech company.

June 16, 2021The Cap Times

The Food and Drug Administration-approved trial will use a form of transplant that replaces a patients bone marrow with alpha-beta T-cell depleted peripheral blood stem cells from closely matched unrelated donors or family members.

May 27, 2021

Over the past two decades, stem cell research at UW-Madison has grown from involving a handful of scientists to nearly 100 from more than 30 schools, colleges and departments.

May 25, 2021Quarterly Magazine, Vol. 23, No. 1

Nine University of WisconsinMadison postdoctoral researchers have been recognized with the inaugural Postdoc Excellence Awards for their teaching, service and mentoring. Daniel Z. Radecki (Comparative Biosciences) received one of these awards.

The defining feature of Dans work with the (UWMadison Postdoctoral Association) and others is his commitment to bettering the lives of all postdocs. He envisions how each event and initiative can best impact the individual, through the lenses of diversity and inclusion, immigration status, postdocs personal lives (e.g. childcare considerations), department/discipline, and more.

Congratulations, Daniel!

April 29, 2021

Researchers at UWMadison have made new photoreceptors from human pluripotent stem cells. However, it remains challenging to precisely deliver those photoreceptors within the diseased or damaged eye so that they can form appropriate connections, says David Gamm, director of the McPherson Eye Research Institute and professor of ophthalmology and visual sciences at the UW School of Medicine and Public Health.

While it was a breakthrough to be able to make the spare parts these photoreceptors its still necessary to get them to the right spot so they can effectively reconstruct the retina, he says. So, we started thinking, How can we deliver these cells in a more intelligent way? Thats when we reached out to our world-class engineers at UWMadison.

Research from the University of WisconsinMadison finds that a new therapeutic approach for heart failure could help restore cardiac function by regenerating heart muscle. In a study recently published in the journal Circulation, the UW team describes its success in improving, in a mouse model, the function of heart muscle by temporarily blocking a key metabolic enzyme after a heart attack. This simple intervention, the researchers say, could ultimately help people regain cardiac function. Our goal was to gain new understanding of how the heart can heal itself following injury at the molecular and cellular level and see if there was a way to restore cardiac function to an earlier state, says UWMadisons Ahmed Mahmoud, professor of cell and regenerative biology in the School of Medicine and Public Health.

Learn more about the research here.April 15, 2021

Grafting neurons grown from monkeys own cells into their brains relieved the debilitating movement and depression symptoms associated with Parkinsons disease, researchers at the University of WisconsinMadison reported today. In a study published in the journal Nature Medicine the UW team describes its success with neurons made from cells from the monkeys own bodies after reprogramming to induced pluripotent stem cells. UWMadison neuroscientist Su-Chun Zhang, whose Waisman Center lab grew the brain cells, said this approach avoided complications with the primates immune systems and takes an important step toward a treatment for millions of human Parkinsons patients. Learn more about their work here.March 1, 2021

The project, led by David Gamm, MD, PhD, director of the McPherson Eye Research Institute and professor of ophthalmology and visual sciences at the UW School of Medicine and Public Health, will develop a transplantable patch to restore vision to members of the armed forces who have been injured by blasts or lasers.December 11, 2020

This week, the NIH Office of Research Infrastructure Programs highlights Dr. Marina Emborg, her WNPRC lab team and their UWMadison colleagues advances in detecting heart disease in Parkinsons and evaluating new therapies that specifically target nerve disease within the human heart.December 2020

Its been 25 years since University of WisconsinMadison scientist James Thomson became the first in the world to successfully isolate and culture primate embryonic stem cells. He accomplished this breakthrough first with nonhuman primates at the Wisconsin National Primate Research Center in 1995, using rhesus monkey cells, then in 1996 with marmoset cells. Thomson then published his world-changing breakthrough on human embryonic stem cell derivation in Science on Nov. 6, 1998.November 6, 2020

EEMs and exosomes each have attractive characteristics as therapeutics, Dr. Hematti, UW-Madisons Department of Medicine, noted. As a cell therapy, EEMs will not proliferate or differentiate to undesirable cell types, which remains a concern for many stem cell therapies. Moreover, EEMs could be generated from a patients own monocytes using off-the-shelf exosomes, resulting in a faster and more facile process compared to autologous MSCs. Alternatively, exosome therapy could be a cell free, shelf-stable therapeutic to deliver biologically active components. Altogether, we believe our studies results support the use of EEMs and/or exosomes to improve ligament healing by modulating inflammation and tissue remodeling, Dr. Vanderby concluded.November 3, 2020

View more news posts

View news archives

Visit link:
Stem Cell & Regenerative Medicine Center University of ...

To Read More: Stem Cell & Regenerative Medicine Center University of …
categoriaCardiac Stem Cells commentoComments Off on Stem Cell & Regenerative Medicine Center University of … | dataNovember 8th, 2021
Read All

Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant…

By Dr. Matthew Watson

BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation.

Excerpt from:
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant...

To Read More: Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant…
categoriaGlobal News Feed commentoComments Off on Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant… | dataNovember 8th, 2021
Read All

Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

By Dr. Matthew Watson

REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA® (pegfilgrastim-cbqv).

Read the original here:
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

To Read More: Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
categoriaGlobal News Feed commentoComments Off on Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 | dataNovember 8th, 2021
Read All

Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

By Dr. Matthew Watson

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.

The rest is here:
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

To Read More: Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
categoriaGlobal News Feed commentoComments Off on Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial | dataNovember 8th, 2021
Read All

Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

By Dr. Matthew Watson

Bagsværd, Denmark, 5 November 2021 – Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period. The STEP 5 trial investigated Wegovy™ vs. placebo, both used with a reduced calorie meal plan and increased physical activity for the treatment of obesity (BMI ?30 kg/m2) or overweight (BMI ?27 kg/ m2) in 304 adults with at least one weight-related comorbidity for 104 weeks (two years).1

View original post here:
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

To Read More: Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
categoriaGlobal News Feed commentoComments Off on Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity | dataNovember 8th, 2021
Read All

Page 21234..1020..»